CA
NZ
UK
AU
IND
US
What Are the Biggest Biotech Catalysts this week, From Kidney Week Data to FDA Holds and Medicare Rates?
It appears to be a recurring pattern in small and mid-sized biotech, and the absence of a headline is not by itself a warning. Shares of companies with no sales are priced on expectations for trials and regulators, so they can move when holders …
Biotech shares are reacting this week to a rare stacking of catalysts: a large medical meeting, a regulatory reversal and a filing decision, all inside a few trading days. With over 12,000 attendees, The American Society of Nephrology's Kidney Week runs from October 21 …
Bitcoin was trading near $81,500 on Friday, October 23, which is approximately 35.4% below the record of roughly $126,200 set on October 6, 2025. The gap corresponds to a year in which the largest cryptocurrency spent much of 2026 in a bear market, then …
On Thursday, October 22, US spot bitcoin ETFs reported net outflows of $635.6 million, the day bitcoin dipped below $80,000 for the first time in about a month. It was the largest daily withdrawal since the $484.9 million reported on October 7, and it …
With a call at 8:00 a.m, Booz Allen Hamilton (NYSE:BAH) reports fiscal second-quarter 2027 results on Friday, October 23. Eastern time. The primary focus is whether revenue can stabilize after the first quarter, when it declined 4.2% to $2.80 billion even as adjusted earnings …
Several companies paired results for the third quarter with new repurchase authorizations this week, though not every program is new. On Tuesday, October 20, General Motors (NYSE:GM) reported a multi-year $20 billion authorization with no expiration date. It comes after a separate $6 billion …
On Monday, October 26, Cadence Design Systems (NASDAQ:CDNS) will discuss third-quarter 2026 results in a webcast, at 2:00 p.m. Pacific Time, as stated in a company notice issued on October 5. The report comes after a second quarter in which the company beat its …
Capital returns are the cash companies send back to shareholders through dividends and buybacks, and this week's reports showed both rising and pausing. General Motors (NYSE:GM) reported a $20 billion buyback on October 20, Columbia Banking System (NASDAQ:COLB) approved as much as $1.2 billion …
Biotechs are pivoting because the economics of ex vivo cell therapy, in which a patient's cells are removed, engineered and returned, are hard to sustain on a small financial position. In-body, or in vivo, approaches promise to skip the manufacturing step, and several developers …
Please wait processing your request...